Pfizer Upgraded by RBC, Outlook Improves
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 hours ago
0mins
Source: Yahoo Finance
- Rating Upgrade: RBC Capital Markets upgraded Pfizer's rating from Underperform to Sector Perform, reflecting a more balanced risk-reward profile after the stock's pullback, indicating a renewed market confidence in Pfizer.
- Valuation Insights: Pfizer currently trades near RBC's one-year forward price-to-earnings estimate of 9 times, with analyst Trung Huynh maintaining a $25 price target while highlighting a 7% dividend yield as a support level for income-focused investors.
- Clinical Trial Developments: RBC noted that two late-stage readouts for Pfizer, one for lung cancer and another for prostate cancer, are expected in mid-2026 and the second half of the year, respectively, which could enhance Pfizer's 2026 outlook and bolster market expectations for future growth.
- Stabilizing Growth: Pfizer is working to stabilize its growth narrative, as recent quarterly results showed solid first-quarter fundamentals, while management pointed to a more constructive market setup later in the year, suggesting potential for improved investor sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.700
Low
24.00
Averages
28.56
High
35.00
Current: 25.700
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves Expanded Use of HYMPAVZI for Hemophilia Treatment in Adolescents
- Expanded Indication: The FDA has approved HYMPAVZI for use in patients aged 12 and older with hemophilia A or B and pediatric patients aged 6 to 11, marking the first availability of a non-factor treatment for this age group, addressing a significant medical need.
- Significant Efficacy: Results from the Phase 3 BASIS trial demonstrated that HYMPAVZI reduced the annualized bleeding rate (ABR) by 93% in adults and adolescents, showcasing its superior efficacy in managing bleeding episodes compared to traditional therapies.
- Simplified Administration: HYMPAVZI offers a once-weekly subcutaneous administration that eliminates the need for routine treatment-related lab monitoring, significantly reducing the treatment burden for patients and caregivers, thereby enhancing adherence to therapy.
- Global Market Potential: With regulatory approvals in over 40 countries, Pfizer is committed to pursuing further global regulatory approvals for HYMPAVZI, aiming to expand its market presence and meet the treatment needs of hemophilia patients worldwide.
See More
Pfizer Upgraded by RBC, Outlook Improves
- Rating Upgrade: RBC Capital Markets upgraded Pfizer's rating from Underperform to Sector Perform, reflecting a more balanced risk-reward profile after the stock's pullback, indicating a renewed market confidence in Pfizer.
- Valuation Insights: Pfizer currently trades near RBC's one-year forward price-to-earnings estimate of 9 times, with analyst Trung Huynh maintaining a $25 price target while highlighting a 7% dividend yield as a support level for income-focused investors.
- Clinical Trial Developments: RBC noted that two late-stage readouts for Pfizer, one for lung cancer and another for prostate cancer, are expected in mid-2026 and the second half of the year, respectively, which could enhance Pfizer's 2026 outlook and bolster market expectations for future growth.
- Stabilizing Growth: Pfizer is working to stabilize its growth narrative, as recent quarterly results showed solid first-quarter fundamentals, while management pointed to a more constructive market setup later in the year, suggesting potential for improved investor sentiment.
See More
Key Takeaways from Wednesday's Investing Club Meeting
- Market Dynamics Impact: Stocks fell on Wednesday as investors weighed a relatively favorable inflation report against President Trump's comments on Iran, with the consumer price index meeting expectations but rising energy prices still pressuring the market, particularly affecting tech stocks.
- FedEx Freight Stock Volatility: FedEx Freight shares dropped 4.5% after Amazon announced plans to expand its trucking services; however, Jim remains optimistic about the company's independent prospects, believing it can unlock more value by focusing on its LTL business.
- Nvidia Stock Performance: Nvidia shares fell another 3% as investors raised cash for upcoming IPOs and AI-related investments; Jim noted that this weakness is more about market dynamics than any deterioration in Nvidia's fundamentals, maintaining a positive long-term outlook.
- Rapid Fire Stock Review: Stocks mentioned at the end of the video included Cracker Barrel, Cava, Chewy, Casey's General Stores, and Pfizer, highlighting the Investing Club's focus on a diversified portfolio.
See More
Latest Wall Street Ratings Overview
- Tesla's Self-Driving Tech: Piper Sandler reiterates Tesla as overweight, highlighting progress in its full self-driving software despite ongoing market skepticism, reflecting competitive pressures in the autonomous driving sector.
- Hyliion Stock Rating: Needham initiates coverage of Hyliion Holdings with a Buy rating and a $9 target, indicating strong performance in power solutions and showcasing the company's market potential and growth momentum.
- Healthcare Market Opportunity: Barclays upgrades Oscar Health from equal weight to overweight, believing the company's single-line exposure to the Individual ACA market provides direct leverage for potential multi-year re-rating, signaling recovery in margins.
- Nvidia Stock Attractiveness: Rosenblatt reiterates Nvidia as a Buy, emphasizing its leadership in AI computing and strong growth visibility, with shares currently trading at a ~35% discount to peers, indicating significant investment value.
See More
Pfizer Reviews Investment Plans in Germany Amid Price Policy Changes
- Investment Review: Pfizer CEO Albert Bourla stated in a letter to Chancellor Friedrich Merz that the company is reviewing its investment timing and scope in Germany due to government proposals aimed at lowering drug prices, which could undermine long-term investment predictability in the pharmaceutical sector.
- Policy Impact: Bourla emphasized that the government's proposals raise questions about the predictability necessary for the pharmaceutical industry, prompting Pfizer to reassess its external engagements and future investment priorities, potentially affecting its market positioning in Germany.
- Industry Reaction: This announcement follows Eli Lilly's decision to halve its $2.3 billion investment in Germany and Boehringer Ingelheim's cancellation of its €900 million plans, both citing the government's healthcare cost-cutting measures, highlighting the industry's sensitivity to policy changes.
- Market Uncertainty: Pfizer's investment review reflects a broader uncertainty within the pharmaceutical industry regarding the future of the German market, which may lead other companies to reconsider their investment strategies in Germany, thereby impacting the overall investment climate in the sector.
See More
Eli Lilly Solidifies Leadership in Obesity Drug Market
- Clinical Trial Data Released: Eli Lilly presented detailed clinical trial data for its experimental drug retatrutide at the American Diabetes Association meeting, confirming that its once-weekly injection offers superior weight loss prospects compared to existing medications, further solidifying its leadership in the obesity drug market.
- Increasing Market Competition: While Lilly maintains a leading position, new data from Roche, AstraZeneca, and Pfizer indicates intensifying competition in the obesity drug market, which may lead to price reductions and more options, potentially impacting Lilly's market share.
- Diverse Patient Choices: Roche's enicepatide demonstrated a 22.7% weight loss in mid-stage trials, while both Lilly and Novo Nordisk are committed to providing multiple drug options to cater to diverse patient needs, emphasizing the importance of personalized treatment.
- Challenges in Side Effect Management: Despite breakthroughs in weight loss efficacy, many drugs still face significant side effect issues, particularly gastrointestinal discomfort associated with GLP-1 and GIP hormones, leading to discontinuation rates as high as 40%, posing challenges for market acceptance of these therapies.
See More
FDA Approves Expanded Use of HYMPAVZI for Hemophilia Treatment in Adolescents
- Expanded Indication: The FDA has approved HYMPAVZI for use in patients aged 12 and older with hemophilia A or B and pediatric patients aged 6 to 11, marking the first availability of a non-factor treatment for this age group, addressing a significant medical need.
- Significant Efficacy: Results from the Phase 3 BASIS trial demonstrated that HYMPAVZI reduced the annualized bleeding rate (ABR) by 93% in adults and adolescents, showcasing its superior efficacy in managing bleeding episodes compared to traditional therapies.
- Simplified Administration: HYMPAVZI offers a once-weekly subcutaneous administration that eliminates the need for routine treatment-related lab monitoring, significantly reducing the treatment burden for patients and caregivers, thereby enhancing adherence to therapy.
- Global Market Potential: With regulatory approvals in over 40 countries, Pfizer is committed to pursuing further global regulatory approvals for HYMPAVZI, aiming to expand its market presence and meet the treatment needs of hemophilia patients worldwide.
See More
Pfizer Upgraded by RBC, Outlook Improves
- Rating Upgrade: RBC Capital Markets upgraded Pfizer's rating from Underperform to Sector Perform, reflecting a more balanced risk-reward profile after the stock's pullback, indicating a renewed market confidence in Pfizer.
- Valuation Insights: Pfizer currently trades near RBC's one-year forward price-to-earnings estimate of 9 times, with analyst Trung Huynh maintaining a $25 price target while highlighting a 7% dividend yield as a support level for income-focused investors.
- Clinical Trial Developments: RBC noted that two late-stage readouts for Pfizer, one for lung cancer and another for prostate cancer, are expected in mid-2026 and the second half of the year, respectively, which could enhance Pfizer's 2026 outlook and bolster market expectations for future growth.
- Stabilizing Growth: Pfizer is working to stabilize its growth narrative, as recent quarterly results showed solid first-quarter fundamentals, while management pointed to a more constructive market setup later in the year, suggesting potential for improved investor sentiment.
See More
Key Takeaways from Wednesday's Investing Club Meeting
- Market Dynamics Impact: Stocks fell on Wednesday as investors weighed a relatively favorable inflation report against President Trump's comments on Iran, with the consumer price index meeting expectations but rising energy prices still pressuring the market, particularly affecting tech stocks.
- FedEx Freight Stock Volatility: FedEx Freight shares dropped 4.5% after Amazon announced plans to expand its trucking services; however, Jim remains optimistic about the company's independent prospects, believing it can unlock more value by focusing on its LTL business.
- Nvidia Stock Performance: Nvidia shares fell another 3% as investors raised cash for upcoming IPOs and AI-related investments; Jim noted that this weakness is more about market dynamics than any deterioration in Nvidia's fundamentals, maintaining a positive long-term outlook.
- Rapid Fire Stock Review: Stocks mentioned at the end of the video included Cracker Barrel, Cava, Chewy, Casey's General Stores, and Pfizer, highlighting the Investing Club's focus on a diversified portfolio.
See More
Latest Wall Street Ratings Overview
- Tesla's Self-Driving Tech: Piper Sandler reiterates Tesla as overweight, highlighting progress in its full self-driving software despite ongoing market skepticism, reflecting competitive pressures in the autonomous driving sector.
- Hyliion Stock Rating: Needham initiates coverage of Hyliion Holdings with a Buy rating and a $9 target, indicating strong performance in power solutions and showcasing the company's market potential and growth momentum.
- Healthcare Market Opportunity: Barclays upgrades Oscar Health from equal weight to overweight, believing the company's single-line exposure to the Individual ACA market provides direct leverage for potential multi-year re-rating, signaling recovery in margins.
- Nvidia Stock Attractiveness: Rosenblatt reiterates Nvidia as a Buy, emphasizing its leadership in AI computing and strong growth visibility, with shares currently trading at a ~35% discount to peers, indicating significant investment value.
See More
Pfizer Reviews Investment Plans in Germany Amid Price Policy Changes
- Investment Review: Pfizer CEO Albert Bourla stated in a letter to Chancellor Friedrich Merz that the company is reviewing its investment timing and scope in Germany due to government proposals aimed at lowering drug prices, which could undermine long-term investment predictability in the pharmaceutical sector.
- Policy Impact: Bourla emphasized that the government's proposals raise questions about the predictability necessary for the pharmaceutical industry, prompting Pfizer to reassess its external engagements and future investment priorities, potentially affecting its market positioning in Germany.
- Industry Reaction: This announcement follows Eli Lilly's decision to halve its $2.3 billion investment in Germany and Boehringer Ingelheim's cancellation of its €900 million plans, both citing the government's healthcare cost-cutting measures, highlighting the industry's sensitivity to policy changes.
- Market Uncertainty: Pfizer's investment review reflects a broader uncertainty within the pharmaceutical industry regarding the future of the German market, which may lead other companies to reconsider their investment strategies in Germany, thereby impacting the overall investment climate in the sector.
See More
Eli Lilly Solidifies Leadership in Obesity Drug Market
- Clinical Trial Data Released: Eli Lilly presented detailed clinical trial data for its experimental drug retatrutide at the American Diabetes Association meeting, confirming that its once-weekly injection offers superior weight loss prospects compared to existing medications, further solidifying its leadership in the obesity drug market.
- Increasing Market Competition: While Lilly maintains a leading position, new data from Roche, AstraZeneca, and Pfizer indicates intensifying competition in the obesity drug market, which may lead to price reductions and more options, potentially impacting Lilly's market share.
- Diverse Patient Choices: Roche's enicepatide demonstrated a 22.7% weight loss in mid-stage trials, while both Lilly and Novo Nordisk are committed to providing multiple drug options to cater to diverse patient needs, emphasizing the importance of personalized treatment.
- Challenges in Side Effect Management: Despite breakthroughs in weight loss efficacy, many drugs still face significant side effect issues, particularly gastrointestinal discomfort associated with GLP-1 and GIP hormones, leading to discontinuation rates as high as 40%, posing challenges for market acceptance of these therapies.
See More
